Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients

Human Immunology

Volumn 69, Issue 4-5, 2008, Pages 266-272

  Kvistborg, Pia ^a   Hadrup, Sine Reker ^b   Svane, Inge Marie ^c   Andersen, Mads Hald ^c   Straten, Per thor ^c  

^a Dandritt Biotech   (Denmark)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer; CD8 T cell; Cytochrome P450 1B1; HLA A1; HLA B35; Tumor associated antigen (TAA)

Indexed keywords

CYTOCHROME P450; HLA A1 ANTIGEN; HLA B35 ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER PATIENT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CYTOCHROME P-450 ENZYME SYSTEM; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA-A1 ANTIGEN; HLA-B35 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; OLIGOPEPTIDES;

EID: 50949104112     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2008.02.007     Document Type: Article

References (28)

1. Murray G.I., Melvin W.T., Greenlee W.F., and Burke M.D. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41 (2001) 297
2. McFadyen M.C., McLeod H.L., Jackson F.C., Melvin W.T., Doehmer J., and Murray G.I. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 62 (2001) 207
3. Maecker B., Sherr D.H., Vonderheide R.H., Bergwelt-Baildon M.S., Hirano N., Anderson K.S., et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 102 (2003) 3287
4. Maecker B., Bergwelt-Baildon M.S., Sherr D.H., Nadler L.M., and Schultze J.L. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer 115 (2005) 333
5. Gilboa E. DC-based cancer vaccines. J Clin Invest 117 (2007) 1195
6. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13 (2007) 54
7. Gabrilovich D.I. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 8 (2007) 2
8. Gribben J.G., Ryan D.P., Boyajian R., Urban R.G., Hedley M.L., Beach K., et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11 (2005) 4430
9. Sosman J.A., and Sondak V.K. Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2 (2003) 353
10. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., and Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50 (1997) 213
11. Letsch A., and Scheibenbogen C. Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. Methods 31 (2003) 143
12. Rininsland F.H., Helms T., Asaad R.J., Boehm B.O., and Tary-Lehmann M. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods 240 (2000) 143
13. Andersen M.H., Bonfill J.E., Neisig A., Arsequell G., Sondergaard I., Neefjes J., et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 163 (1999) 3812
14. Andersen M.H., Kvistborg P., Becker J.C., and thor Straten P. Identification of an HLA-A1 restricted CTL epitope from Mcl-1. Leukemia 19 (2005) 1084
15. Andersen M.H., Becker J.C., and thor Straten P. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Disc 4 (2005) 399
16. Nagorsen D., Scheibenbogen C., Marincola F.M., Letsch A., and Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 9 (2003) 4296
17. Meier A., Reker S., Svane I.M., Holten-Andersen L., Becker J.C., Søndergaard I., et al. Spontaneous CTL responses against peptides derived from the Taxol resistance associated gene-3 (Trag-3) protein in cancer patients. Cancer Immunol Immunother 54 (2005) 219
18. McFadyen M.C., Melvin W.T., and Murray G.I. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 3 (2004) 363
19. Valmori D., Dutoit V., Rubio-Godoy V., Chambaz C., Lienard D., Guillaume P., et al. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res 61 (2001) 509
20. Cibotti R., Kanellopoulos J.M., Cabaniols J.P., Halle-Panenko O., Kosmatopoulos K., Sercarz E., et al. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 89 (1992) 416
21. Maecker B., Bergwelt-Baildon M.S., Anderson K.S., Vonderheide R.H., Anderson K.C., Nadler L.M., et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol 141 (2005) 558
22. Strehl B., Seifert U., Kruger E., Heink S., Kuckelkorn U., and Kloetzel P.M. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 207 (2005) 19
23. Vambutas A., DeVoti J., Nouri M., Drijfhout J.W., Lipford G.B., Bonagura V.R., et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23 (2005) 5271
24. Luiten R.M., Demotte N., Tine J., and van der Bruggen P. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens 56 (2000) 77
25. Schultz E.S., Zhang Y., Knowles R., Tine J., Traversari C., Boon T., et al. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 57 (2001) 103
26. Benlalam H., Linard B., Guilloux Y., Moreau-Aubry A., Derre L., Diez E., et al. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol 171 (2003) 6283
27. Terakura S., Murata M., Warren E.H., Sette A., Sidney J., Naoe T., et al. A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. Transplantation 83 (2007) 1242
28. Luby T.M., Cole G., Baker L., Kornher J.S., Ramstedt U., and Hedley M.L. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. Clin Immunol 112 (2004) 45